Although the effect of age on body composition has been intensively discussed during the past 20 years, we do not have a uniform definition of sarcopenia. A suitable definition of low, lean body mass should be based on magnetic resonance imaging (MRI) estimates of muscle mass. Using recent MRI data of a population of 446 healthy free-living Caucasian volunteers (247 females, 199 males) age 18-78 years, a low skeletal muscle mass and sarcopenia were defined as a skeletal muscle mass 41 and 42 s.d. below the mean value obeserved in younger adults at age 18-39 years. The cutoffs for low muscle mass according to the skeletal muscle index (skeletal muscle mass/(height) 2 ) or the appendicular skeletal muscle mass index (skeletal muscle mass of the limbs/(height) 2 ) were 6.75 or 4.36 kg/m 2 for females and 8.67 or 5.54 kg/m 2 for males, respectively. On the basis of these cutoffs, prevalences of sarcopenia in the group of adults at 460 years are calculated to be 29% in females and 19.0% in males. Faced with different sarcopenic phenotypes (that is, sarcopenia related to frailty and osteopenia; sarcopenic obesity related to metabolic risks; cachexia related to wasting diseases), future definitions of sarcopenia should be extended to the relations between (i) muscle mass and adipose tissue and (ii) muscle mass and bone mass. Suitable cutoffs should be based on the associations between estimates of body compositions and metabolic risks (for axample, insulin resistance), inflammation and muscle function (that is, muscle strength).
INTRODUCTION
The sarcopenic phenotype is characterized by an absolute or relative reduction of muscle mass with and without losses in body weight. 1 Skeletal muscle makes up~50% of total body protein. A significant loss in skeletal muscle mass impairs metabolism, immunocompetence and strength. Thus, sarcopenia relates to frailty, falls and bone fractures, disability, institutionalization and hospitalization. In a clinical setting, a low muscle mass increased hospital stay and decreased survival. In overweight individuals, low muscle mass may be obscured by body weight. Vice versa, underweight subjects may have a normal muscle mass. 2 Sarcopenia relates to aging, inactivity and disease. Muscle mass decreases by about 30% between the ages of 20 and 80 years, that is, roughly about 6 kg. 3 In addition, healthy older subjects lost 1 kg muscle mass in response to 10 days of bedrest and immobilization. 4 During the course of wasting diseases, loss of muscle mass is rapid and consistent but variable, due to diseaserelated factors (for example, inflammation). In critically ill patients, whole-body net protein loss is between 2 and 4 g/kg body weight x d, which is to a great part at the cost of skeletal muscle. 5 In clinical practice, separation of age-related and disease-related changes in body composition remains difficult.
DEFINING LOSS OF SKELETAL MUSCLE MASS, METHODOLOGICAL ASPECTS
Defining sarcopenia depends on accurate assessment of skeletal muscle mass (SM). DXA (dual X-ray absorptiometry), BIA (bioelectrical impedance analysis) and imaging technologies (MRI, magnetic resonance imaging; CT, computed tomography) are used to estimate whole-body and regional SM. 6 When compared with DXA and BIA, imaging technologies are precise and valid; MRI and CT are criterion methods for measuring muscle mass. 7 CT and MRI allow reconstruction of muscle volumes. Transversal images were taken at different distances that is, at a slice thickness of 10 mm. Cross-sectional organ and tissue areas are determined by hand or by automatic scanning. Calculation of muscle volume is based on the sum of cross-sectional areas multiplied by slice thickness and the distance between scans (for example, 2 or 5 cm). Muscle volume multplied by muscle density then gives muscle mass. Muscle tissue density is assumed to be constant, that is, 1.04 kg/l. 8 The technical error relates to fuzzy borders or embedded shapes, for example, blood vessels. In addition, the biological variance of muscle tissue density (that is, with age, obesity, weight loss and/or disease) is presently not taken into account. Cadaver validation of CT-or MRI-derived skeletal muscle measurements showed a high correlation between the results of the two estimates (r = 0.99). 8 Presently, we do not have a uniform definition of sarcopenia. However, various cutoffs for low muscle mass and sarcopenia have been defined based on different cross-sectional databases. In these population studies, SM or skeletal muscle index (SMI, defined as either SM/body weight × 100 in Janssen et al. 9 or SM/(height) 2 in Cruz-Jentfort et al. 7 ) or either appendicular lean soft tissue (ALST, that is, the sum of appendicular SM plus skin and connective tissue), appendicular-SMI (that is, muscle mass of the limbs; ASMI = ALST/(height) 2 ), fat free mass (FFM) or fat-free mass index (FFMI = FFM/(height) 2 ) were used. In addition, genderspecific mean values for healthy adults aged 18 to 39 years were taken as reference. Then, sarcopenia was defined as SMI (or ASMI or FFMI) 41 and 42 s.d. below the mean value (that is, class 1 and class 2 sarcopenia, respectively). 7 Imaging technologies cannot be used in greater number of patients and in population studies owing to the high costs, limited access and lack of feasibility. Therefore, huge reference databases on sex-specific whole-body MRI or CT estimates of organ and tissue masses do not exist presently. In practice, some authors have used single CTscans as an estimate of whole-body muscle mass. In the longitudinal Health, Aging and Body Composition Study on men and women between the ages of 70 and 79 years, midthigh muscle cross-sectional area (CSA; as assessed by CT) rather than whole-body muscle mass was measured. 10 In that aged population, mean total thigh muscle area was 129.5 cm 2 in white men and 85.5 cm 2 in white women, respectively. In a 12-year longitudinal study on twelve healthy sedentary men, thigh muscle (as assessed by CT) area decreased from 136 to 116 cm 2 with annual reduction rate of 1.4%. 3 In addition, due to correlation between thigh muscle area and body weight, thigh muscle CSA is also expressed as cm 2 /per kg body weight. In the Korean Sarcopenic Obesity Study, the thigh muscle CSA/weight ratio was 1.9 cm 2 /kg (78% male subjects, mean age 49 years) for metabolically healthy normal weight subjects.
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Other authors have used CT abdominal scans at the level of the third lumbar vertebra (L3) as an estimate of sarcopenia in cancer patients; there was a close association between that single scan and whole-body muscle mass. 12 CT image analysis (that is, muscle area in cm 2 ) is based on Hounsfield units (HU), that is, selecting pixels between − 29 to 150 for skeletal muscle. For comaprison, the interval from − 190 to − 30 HU reflects adipose tissue, whereas the range between 0 and 29 HU covers low-density muscle pixels, that is, intra-and extramyocellular lipid content in muscle. Whole-body FFM can be calculated from skeletal muscle areas at L3 using a regression analysis based on DXA estimates of FFM. In cancer patients, the sex-specific cutoffs for L3 skeletal muscle index (muscle area at L3/(height)
2 ) associated with increased mortality were 52.4 and 38.5 cm 2 /m 2 for men and women, respectively. 13 More recently, these authors have improved the cutoffs to 55.4 and 38.9 cm 2 /m 2 for men and women, respectively.
14 For routine assessment of muscle mass, DXA or BIA estimates have been and are still being used in epidemiology and clinical practice. Sets of cross-sectional reference data were used for defining the cutoffs for low muscle mass and/or low FFM, and, thus, sarcopenia. 9, [15] [16] [17] Reference data are sparse for older people, for example, above 80 years of age. DXA and BIA instruments are widely available. So far, the different cutoffs published are varied from each other. In addition, different authors have used either − 1or − 2 s.d. of their estimates as cutoffs. There are some inconsistencies in the terminologies and definitions, techniques and methodological issues. For example, BIA measures body water and muscle mass is calculated from FFM by assuming a fixed hydration of FFM. Using DXA, ALST or ASM relates to a fat-and bone mineral-free component of lean mass of the four limbs. DXA estimates of muscle mass are frequently given as ASMI, which differs from SMI by the skeletal muscle mass of trunk and head. ASM estimated by DXA had been validated against total-body SM quantified by MRI in healthy adults. 18 ALST was highly correlated with total-body SM (R 2 = 0.96), although age and sex (but not race) were two additional predictor variables. SM-ALST ratio was 1.15 and 1.13 in men and women, respectively, with corresponding coefficients of variation of 5.2% and 7.1%; 18 this ratio decreased with age. In a final model, total-body SM was predicted from ALST by 17 Using BIA, absolute muscle mass rather than appendicular muscle mass was predicted and the estimates were expressed as SMI. 7 The BIA equation used was cross-validated against MRI measures of whole-body muscle mass in a subgroup of 269 men and women.
9,19 SM(kg) can be calculated by
(height in cm, men 1, women 2, age in years). In that study on a nationally representative sample of the US population, a Valhalla 1990B Bio-Resistance Body Composition Analyzer was used at a standard frequency 50 kHz at 800 A. 9 The standard error of the BIA-estimate for predicting SM was 9%.
SMI cutoffs were 8.51-10.75 and o8.50 kg/m 2 for moderate and severe sarcopenia in men with corresponding values of 5.76-6.75 and o 5.75 kg/m 2 in women, respectively. 7 Cutoffs for whole-body FFMI without bone, determined by BIA were o14.6 kg/m 2 in men and o 11.4 kg/m 2 in women. 20 It should be mentioned that FFM is made up of skeletal muscle and other organs, such as the liver, kidneys, brain and heart and also connective tissue. The different components of FFM may be differentially affected by age, obesity ,weight loss or underweight, and/or diseases. In a huge BIA reference database, there was no age effect and FFMI was insensitive to show the age-related decrease in muscle mass. 20, 21 However, BIA estimates of muscle mass had a mass-independent association with skeletal muscle function, that is, the impedance parameters are related to hand grip strength. 16, 22 As for DXA-and BIA-derived estimates of muscle mass, a direct measurement by MRI or CT is recommended in cases of fluid overload, cancer patients with large tumor masses and for obese patients. 17 Presently, there is no expert consensus as to the methodology to be used for routine assessment of SM. 7, 20 MRI ESTIMATES OF WHOLE-BODY SM Until to now, population reference data for whole-body and regional muscle mass using imaging techniques (that is, MRI) have been reported in only one study. 23 This is the most comprehensive data set on skeletal muscle. These data had been obtained about [15] [16] [17] [18] [19] [20] With respect to regional muscle mass, gender differences were greater in the upper body. Within both genders, about 50% of the subject variance in SM was explained by height and weight. There was a decrease in SM with age. Relative muscle mass decreased in the third decade, whereas, a significant decrease in absolute muscle mass was seen after the 5th decade. At an age above 70 years, the mean muscle mass was 18.0 kg (women) and 27.8 kg (men), respectively. 23 The decrease in SM with age was mainly explained by a decrease in the lower body. These unique data can be used as comparative standards. However, to the best of our knowledge, the data 23 have not been used for defining sarcopenia cutoffs and thus, have not been included into geriatric assessment.
As for today, there is a second reference data base on MRIderived body composition in a larger group of subjects in Kiel, Northern Germany. Between 2002 and 2013, 446 healthy freeliving Caucasian volunteers (247 females, 199 males) aged between 18 and 78 years had been recruited to participate in different studies, in which whole-body MRI examinations had been performed; all these studies were done at the Institute of Human Nutrition and Food Science of the University of Kiel. [24] [25] [26] [27] [28] [29] The data were included into the database of the Reference Centre of Body Composition. Our study population is characterized in Tables 1-3 . The mean BMI of our study population is 30.2 kg/m 2 in females and 27.9 kg/m 2 in males, respectively. Thus, our study population is overweight. Figure 1 ).On the basis of these cutoffs, prevalences of low muscle mass (and thus class 1 sarcopenia) in the group of adults at 460 years are calculated to be 29% in females and 19.0% in males. These are considrably high numbers.
TAKING INTO ACCOUNT FAT MASS, FAT DISTRIBUTION AND BONE MINERAL CONTENT
Age-related changes in muscle mass are associated with changes in AT mass and bone mineral content (BMC). Thus, the sarcopenic phenotype not only relates to skeletal muscle but also refers to fat mass and BMC. However, sarcopenia, sarcopenic obesity and cachexia share a common phenotype that is characterized by reductions in the amount, composition and function of skeletal muscles. Sarcopenia itself is characterized by reduced muscle mass and muscle strength. In a merely sarcopenic subject, fat mass is normal or slightly increased but BMC is frequently low. The phenotype shows a close association between low muscle mass, frailty and osteopenia. In sarcopenic obesity, reduced muscle mass is associated with increased fat mass. The latter predominantly relates to increased visceral adipose tissue (VAT) and Abbreviations: CRP; C-reactive protein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein. *Po0.05 difference between age groups within females using Kruskal-Wallis-Test. † Po0.05 difference between age groups within males using Kruskal-Wallis test.
intermuscular fat. The sarcopenic obese phenotype is associated with metabolic disturbances related to insulin resistance and inflammation of AT. Some authors consider this phenotype as a late manifestation of obesity. 31 Finally, in the cachectic patient (frequently seen with organ failure or malignancy), muscle mass as well as fat mass are both reduced, these patients suffer from wasting and are frequently underweight. In a free-living elderly population, the prevalences of either sarcopenia or sarcopenic obesity increases with age, at ages 480 years about 30% are considered as sarcopenic with about 10% being sarcopenic obese subjects. 31 With aging, whole-body fat mass increases but may also decrease. However, waist circumference (WC), VAT and VAT in proportion to total body fat increases, suggesting an age-related Tables 1-3. re-distribution of fat from peripheral to central fat depots. [31] [32] [33] Beyond the age 70 years the prevalence of elevated WC at normal BMI increases with age and may exceed 20% and 40% in females and males, respectively. 33 The WC/VAT ratio also increases, suggesting that for a given WC, VAT is higher in older than in younger females and males. 34 Detailed BCA by MRI reveals the age-related shift from subcutaneous adipose tissue (SAT) to VAT: In both sexes, SAT decreases but VAT increases with age. 35, 36 Using the Kiel MRI database, cutoffs for VAT and the VAT/ ATratio were 2.6 kg and 0.09 in females with corresponding values of 3.47 kg and 0.21 in males (Figure 1) . In older subjects, the prevalences of elevated VAT or VAT/ATratio were 30.1% and 22.6% in females and 56.0% and 27.0% in males, respectively.
BMC decreases with age. 37, 38 This is also seen in the Kiel MRI database population (Figure 1 ). Cutoffs for low BMC were calculated as 1.97 and 2.49 kg in females and males, respectively. Using these cutoff values in a group of subjects at age 460 years, the prevalence of low BMC was 25.8% in women and 15.0% in men.
DEFINING SARCOPENIA BASED ON THE RELATIONSHIPS BETWEEN ORGANS AND TISSUES
With weight loss, there are changes in several body components. Alterations in the individual components of body composition are closely interrelated. Thus, regulation of body weight seems to be more based on those relations rather than on organ and tissue masses themselves. 39 Fat mass has a strong influence on weight loss-associated changes in either fat mass or FFM; the higher the fat mass, the lower is the proportion of lean mass lost with weight loss. 39 This is also reflected by the observation that the muscle-AT ratio decreases with advancing adiposity. 35 There are further sexdependent and regional differences in this association. In men, with increasing adiposity, the ratio of muscle/AT declines faster at the trunk when compared with the extremities. 35 In women, with higher fat mass, the ratio of muscle/AT declines faster at the extremities when compared with the trunk. 35 Even in older adults, a high fat mass predicted the loss of lean mass. 40 With age, body fat in part replaces lean mass. Concomitantly, there is a redistribution from SAT to VAT and ectopic fats in muscle. Besides fat infiltration into muscle tissue, the age-related losses in muscle mass and FFM are partly obscured by the replacement through extracellular water and connective tissue. In addition, internal organs like the liver and kidneys also change with age and decrease in their relative sizes. 31, 41 All these data suggest that weight loss and age-related changes in masses of organs, tissues and body components are related to each other that seems to be fixed, and thus, most probably under control. Intra-individually, the relationships between organ and tissue masses are fixed over the whole period of weight loss. However, there is a high inter-individual variance in these relationships. Body weight and body composition are under genetic and endocrine control. Communication between organs and tissues is brought about by numerous cross-talks between organs and tissues, related to their masses, their functions and probably inflammation. 42 Then, changes in body composition with weight loss go together with and partly result from altered or even disturbed cross-talks between organs and tissues. It is tempting to speculate that aging is associated with some loss of control and alterations in inter-organ/tissue communication.
To summarize, assessment of sarcopenia involves an examination of the relationships between organs and tissues rather than merely their individual masses. Future definitions of sarcopenia comprise a functional body composition approach including (i) the masses of organs and tissues, (ii) between organ/tissue masses relationships and (iii) between organ and between tissue cross-talks. To follow that idea, Figure 2 thus gives our population data and first cutoffs for the ASMI/VAT ratio as well as the ASMI/BMC ratio. Both ratios decreased with age. Following that concept, cutoffs for females and males were 42.6 and 38.0 kg/m 2 for the ASMI to VAT/AT ratio, resulting in prevalences of low values of 17.2% and 53.7% in subjetcts aged 4 60 years, respectively. The corresponding data for the ASMI/BMC ratio are 1.75 and 1.85 kg/m 2 /kg, with prevalences of low values of 7.5% and 13.0%.
HEALTH RISKS RELATED TO DIFFERENT DEFINITIONS OF SARCOPENIA
The concept of functional body composition integrates body components into regulatory systems by relating body components to their corresponding in vivo function and metabolic processes. 42 Age-related changes in body composition have implications for health and body function. Different phenotypes of sarcopenia have thus to be seen in relation functional and health aspects. Then, sarcopenia is related to a loss of muscle strength. In addition, sarcopenic obesity is related to insulin resistance and metabolic disturbances. And finally, cachexia is related to disease, activity and inflammation. Using the present Kiel MRI database, the impact of the different sarcopenic phenotypes on metabolic health risks, inflammation and muscle strength is shown in Table 4 .
PERSPECTIVE
Although the effects of age and diseases on body composition have been intensively discussed during the past 20 years, we still do not have a uniform definition of sarcopenia. 1, 7, 9, 15, 19, 31, 43 A suitable definition of low lean body mass should be based on MRI estimates of muscle mass. Cutoffs derived from DXA and BIA estimates of muscle mass have to be cross-validated against MRI data. Future definitions of sarcopenia have to take into account its different sarcopenic phenotypes and should not only be based on muscle mass but also have to include skeletal muscle VAT and skeletal muscle BMC relationships. These relationships should be seen in the context of inter-organ and inter-tissue cross-talks that are likely to be affected by aging, lifestyle and/or disease. The concept of functional body composition then relates masses of organs and tissues to body functions and health risks, which vice versa affect body composition. Thus, beyond normative approaches, this idea will serve as a future basis of defining suitable cutoffs of organ and tissue masses as well as inter-organ/ tissue relations. This will open a new dimension of sarcopenia research.
